Clinical trials: Hepatitis B Virus Related Cirrhosis
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN RESCU (NCT05832229)
- Testing
- Rosuvastatin
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cirrhosis, Alcohol Related Liver Disease
Clinical Characteristics of Recompensation
Recompensation in decompensated liver cirrhosis is an emerging clinical endpoint; however, standardized criteria and long-term prognostic data are currently lacking.
- Conditions
- Cirrhosis, Alcohol Related Liver Disease, HBV (Hepatitis B Virus), Recompensation
- Trial name
- NCT07651683
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Cohort Study
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN-C (NCT05740358)
- Where
- 14 sites in United States
- Volunteers
- 1,222 people
- Sponsor
- Northwestern University
Hepatitis B, Chronic, Fibrosis
Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients
This study evaluates generic emtricitabine(FTC) plus adefovir dipivoxil in Chinese naive HBV related cirrhosis patients. Patients were divided into 2 groups: compensated HBV related cirrhosis patients and decompensated HBV…
- Trial name
- NCT02327689
- Testing
- Emtricitabine plus adefovir dipivoxil
- Volunteers
- 400 people
- Sponsor
- Asian-Pacific Alliance of Liver Disease, Beijing
Hepatitis B Virus-Related Hepatocellular Carcinoma
The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy
Hepatitis B virus (HBV) infection is a global health problem, especially in the endemic area like Taiwan, where there are more than 3 million chronic hepatitis B carriers.
- Trial name
- CTEAM (NCT01957618)
- Where
- Taiwan
- Volunteers
- 1,500 people
- Sponsor
- National Taiwan University Hospital
Hepatitis B, Liver Cirrhosis
Entecavir for Decompensated HBV Cirrhosis
Entecavir (ETV) and tenofovir (TDF) are the first-line drugs for treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV infection gradually progress to liver cirrhosis.
- Trial name
- NCT03345498
- Testing
- Entecavir
- Where
- India
- Volunteers
- 32 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
HEPATITIS B CHRONIC, Cirrhosis, Liver
Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis
This study aims to establish a prospective, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial cohort.
- Conditions
- HEPATITIS B CHRONIC, Cirrhosis, Liver, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07544121
- Testing
- Babao Dan Capsule, Babao Dan Capsule simulant
- Volunteers
- 1,034 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cirrhosis, Liver, Hepatocellular Carcinoma (HCC)
Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study
This study aims to establish a prospective, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial cohort.
- Conditions
- Cirrhosis, Liver, Hepatocellular Carcinoma (HCC), HEPATITIS B CHRONIC
- Trial name
- NCT07481032
- Testing
- Biejia-Ruangan compound, Biejia-Ruangan compound simulant
- Volunteers
- 1,034 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B Virus, HIV
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
This is a prospective HIV cohort that aims to establish causes of liver disease among HIV-infected individuals in Zambia, including viral hepatitis and alcohol.
- Conditions
- Hepatitis B Virus, HIV, Antiretroviral Therapy, Africa
- Trial name
- NCT02060162
- Testing
- Standard of care
- Where
- Zambia
- Volunteers
- 897 people
- Sponsor
- University of Alabama at Birmingham
Hepatitis B Virus Related Cirrhosis
Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV
Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B Virus (HBV) is one of most etiologies of Liver cirrhosis in China.
- Trial name
- NCT02241616
- Testing
- Entecavir+Fuzheng Huayu+TCM Granule
- Where
- 20 sites in China
- Volunteers
- 350 people
- Sponsor
- ShuGuang Hospital
Chronic Hepatitis B
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown.
- Trial name
- NCT04939441
- Testing
- Tenofovir alafenamide
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Jidong Jia
Hepatitis B, Portal Hypertension
Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial
To evaluate whether atorvastatin can improve portal hypertension in patients with chronic hepatitis B related compensated cirrhosis with portal hypertension
- Trial name
- STAPH (NCT05483894)
- Testing
- Atorvastatin 10mg
- Volunteers
- 36 people
- Sponsor
- Samsung Medical Center
Chronic Hepatitis B, Hepatic Fibrosis
Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD
Hepatic steatosis and insulin resistance are associated with severity of fibrosis in non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C.
- Conditions
- Chronic Hepatitis B, Hepatic Fibrosis, Fatty Liver
- Trial name
- NCT02031913
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Boramae Hospital
HBV Infection, Chronic Hepatitis B
Population-wide Research for HBV-related Liver Diseases in Maoming City
Hepatitis B virus (HBV) infection is a major public health problem and chronic HBV infection affects about 296 million people worldwide and is the leading etiology of cirrhosis and hepatocellular carcinoma globally.
- Conditions
- HBV Infection, Chronic Hepatitis B, Cirrhosis, HCC
- Trial name
- PreMAO (NCT06184347)
- Testing
- Rapid tests for HBsAg
- Volunteers
- 3,700,000 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B, Liver Fibrosis
Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis
Compared to TDF, peginterferon alfa 2a may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients.
- Trial name
- NCT03957629
- Testing
- Tenofovir Disoproxil Fumarate, PEG-Interferon alfa 2a
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
HBV, Alcoholic Hepatitis
Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
The purpose of this study is to recruit a random and representative sample of individuals within several Zambian communities for markers of Hepatitis B Virus (HBV) and to characterize chronic HBV infection and indications for…
- Conditions
- HBV, Alcoholic Hepatitis, Liver Fibroses
- Trial name
- HEP-ZED (NCT03149627)
- Testing
- Estimates - prevalence of lifetime/chronic HBV infection
- Where
- Zambia
- Volunteers
- 5,003 people
- Sponsor
- University of Alabama at Birmingham
Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
The goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated cirrhosis who are receiving effective treatment for the cause of…
- Conditions
- Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-Related Liver Disease
- Trial name
- LEAD-2 (NCT07087041)
- Where
- 28 sites in China
- Volunteers
- 735 people
- Sponsor
- Beijing Friendship Hospital
Cirrhosis of Liver Due to Hepatitis B (Disorder)
Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients
The study aims to demonstrate that whether treatment of nucleoside （acid）analogues (NAs) plus pegylated interferon (Peg IFN) α-2b for those NAs treated, low level of HBsAg, hepatitis B related compensatory cirrhosis patients will…
- Trial name
- NCT03969017
- Testing
- pegylated interferon (Peg IFN)α-2b, Nucleoside （acid）analogue (NAs)
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Liver Cirrhosis, Hepatitis B
Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis
Though newly reported HBV infection and HBsAg prevalence in China have greatly decreased, patients who had been chronically infected with HBV, especially those with liver cirrhosis cause great burden on public health care.
- Trial name
- NCT01720238
- Testing
- Entecavir, Lamivudine plus Adefovir Dipivoxil
- Where
- 8 sites in China
- Volunteers
- 621 people
- Sponsor
- Beijing Friendship Hospital
Hepatitis B, Liver Fibrosis
A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers
The aim of our study is to validate the non-invasive model which was constructed by our previous study for evaluating liver fibrosis or cirrhosis caused by hepatitis B virus in mainland China and to find a therapeutic regimen to…
- Trial name
- NCT03568578
- Testing
- Entecavir 0.5 mg, Anluohuaxian Pill 12g
- Where
- 18 sites in China
- Volunteers
- 450 people
- Sponsor
- Peking University First Hospital